Literature DB >> 8649791

A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines.

E M Algar1, T Khromykh, S I Smith, D M Blackburn, G J Bryson, P J Smith.   

Abstract

The response of the CML-BC cell line, K562, the myelomonocytic cell line MM6 and the promyelocytic leukaemia cell line HL-60, to a 15 mer WT1 antisense oligonucleotide, targeted to the translation initiation site of the WT1 mRNA was examined. K562 cells exposed to 0.4 microM antisense oligonucleotide showed markedly reduced proliferation which was associated with reduced cell viability. Sense, scrambled and mutant antisense oligonucleotides had no effect on the proliferation of K562 cells. MM6 cells exposed to 0.4 microM antisense oligonucleotide also showed significantly reduced cellular proliferation which was also accompanied by loss of cell viability. In the K562 and MM6 antisense cultures that exhibited reduced cell viability, both DNA fragmentation and morphological features consistent with apoptosis could be identified. In contrast the growth of HL-60 cells was unaffected by exposure to 0.4 microM antisense oligonucleotide. In each of the cell lines examined, WT1 antisense oligonucleotide abrogated WT1 protein expression, and analysis of WT1 coding sequence in these cells showed that no oncogenic point mutations in the gene were present. We propose therefore that in some myeloid leukaemia cell lines, the expression of a normal WT1 protein is necessary for cell proliferation and that it plays a role in maintaining the viability of some leukaemia cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649791

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 2.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.

Authors:  Ann Van Driessche; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-01-30

3.  The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells.

Authors:  L W Ellisen; N Carlesso; T Cheng; D T Scadden; D A Haber
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

4.  Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities.

Authors:  N Tatsumi; N Hojo; O Yamada; M Ogawa; Y Katsura; S Kawata; E Morii; H Sakamoto; R Inaba; A Tsuda; I Fukuda; N Moriguchi; H Hasuwa; M Okabe; F Fujiki; S Nishida; H Nakajima; A Tsuboi; Y Oka; N Hosen; H Sugiyama; Y Oji
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

5.  Expression of the Gfi-1 gene in HTLV-1-transformed T cells.

Authors:  I Sakai; H Yamauchi; M Yasukawa; H Kohno; S Fujita
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

Review 6.  Tumor Vaccines for Malignant Gliomas.

Authors:  Visish M Srinivasan; Sherise D Ferguson; Sungho Lee; Shiao-Pei Weathers; Brittany C Parker Kerrigan; Amy B Heimberger
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

7.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

8.  Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.

Authors:  Che Kang Lim; Yeow Tee Goh; William Y K Hwang; Liam Pock Ho; Li Sun
Journal:  Biomark Insights       Date:  2007-08-08

9.  Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma.

Authors:  Sohei Yamamoto; Hitoshi Tsuda; Tsunekazu Kita; Kazunari Maekawa; Kazuyuki Fujii; Kazuya Kudoh; Kenichi Furuya; Seiichi Tamai; Johji Inazawa; Osamu Matsubara
Journal:  Virchows Arch       Date:  2007-06-27       Impact factor: 4.064

Review 10.  Wilms tumor gene (WT1) expression as a panleukemic marker.

Authors:  Hans D Menssen; Jan M Siehl; Eckhard Thiel
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.